<p>Beam Therapeutics Inc.（纳斯达克代码：BEAM - 获取免费报告）在目前覆盖该公司的十六家研究机构中获得了 “适度买入” 的平均评级，MarketBeat 报道称。一位研究分析师给予该股票卖出评级，两位给予持有评级，十一位给予买入评级，两位给予强烈买入评级。在过去一年中更新了对该股票覆盖的分析师中，平均十二个月目标价为 45.5833 美元。</p>
<p>获取 <strong>Beam Therapeutics</strong> 的提醒：</p>
<ul>
<li>MarketBeat 周报 – 3/4 – 3/8</li>
</ul>
<p>一些股票研究分析师最近对 BEAM 股票发表了评论。HC Wainwright 在 10 月 10 日星期五的研究报告中重申了 “买入” 评级，并设定了 80.00 美元的价格目标。Jefferies Financial Group 在 10 月 9 日星期四的研究报告中开始覆盖 Beam Therapeutics 股票。他们给予该股票 “买入” 评级，并设定了 41.00 美元的价格目标。Benchmark 在 11 月 17 日星期一的报告中重申了对 Beam Therapeutics 股票的 “投机性买入” 评级。华尔街 Zen 在 11 月 8 日星期六的报告中将 Beam Therapeutics 股票的评级从 “持有” 下调至 “卖出”。最后，Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Beam Therapeutics 股票的 “卖出（d-）” 评级。</p>
<p><strong>阅读我们关于 BEAM 的最新研究报告</strong></p>
<h2>Beam Therapeutics 股票下跌 2.3%</h2>
<ul>
<li>Beam Therapeutics 因基因治疗许可付款而大幅上涨</li>
</ul>
<p>BEAM 股票在星期三开盘价为 26.48 美元。Beam Therapeutics 的 12 个月低点为 13.52 美元，12 个月高点为 35.25 美元。该公司的 50 日移动平均线为 24.97 美元，200 日移动平均线为 21.13 美元。该公司的市值为 26.9 亿美元，市盈率为 -5.98，贝塔值为 2.21。</p>
<p>Beam Therapeutics（纳斯达克代码：BEAM - 获取免费报告）最近在 11 月 4 日星期二发布了季度财报。该公司报告本季度每股收益（EPS）为 -1.10 美元，低于市场共识预期的 -0.98 美元，差距为 -0.12 美元。Beam Therapeutics 的股本回报率为 -42.86%，净利润率为 -744.41%。该公司本季度的收入为 970 万美元，而分析师预期为 1283 万美元。在去年同期，该公司每股收益为 -1.17 美元。与去年同期相比，该公司的季度收入下降了 32.2%。研究分析师预计 Beam Therapeutics 今年的每股收益将为 -4.57 美元。</p>
<h2>Beam Therapeutics 的机构交易</h2>
<ul>
<li>CRISPR Therapeutics 是基因编辑领域的 NVIDIA 吗？</li>
</ul>
<p>一些对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Larson Financial Group LLC 在第三季度将其在 Beam Therapeutics 的持股增加了 4370.5%。Larson Financial Group LLC 现在拥有 1,967 股该公司的股票，价值 48,000 美元，此前在上个季度购买了额外的 1,923 股。Van ECK Associates Corp 在第三季度将其在 Beam Therapeutics 的持仓增加了 48.7%。Van ECK Associates Corp 现在拥有 2,158 股该公司的股票，价值 52,000 美元，此前在上个季度购买了额外的 707 股。Allworth Financial LP 在第二季度将其在 Beam Therapeutics 的持股增加了 7080.0%。Allworth Financial LP 现在拥有 2,513 股该公司的股票，价值 43,000 美元，此前在上个季度购买了额外的 2,478 股。大和证券集团在第二季度将其在 Beam Therapeutics 的持股增加了 1248.8%。大和证券集团现在拥有 3,817 股该公司的股票，价值 65,000 美元，此前在上个季度购买了额外的 3,534 股。最后，未来资产全球投资有限公司在第二季度将其在 Beam Therapeutics 的持股增加了 43.4%。未来资产全球投资有限公司现在拥有 3,884 股该公司的股票，价值 66,000 美元，此前在上个季度购买了额外的 1,175 股。目前 99.68% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Beam Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Beam Therapeutics Inc. 是一家生物技术公司，专注于为美国患有严重疾病的患者开发精准基因药物。它开发了 BEAM-101 用于治疗镰状细胞病或 β-地中海贫血；以及 BEAM-302，一种针对严重 α-1 抗胰蛋白酶缺乏症的肝靶向 LNP 配方；BEAM-201，一种抗 CD7 CAR-T 产品候选药物，目前正在进行 1/2 期临床试验，用于治疗难治性 T 细胞急性淋巴细胞白血病/T 细胞淋巴母细胞瘤；以及 BEAM-301，一种用于治疗糖原储存病 1a 的肝靶向 LNP 配方。</p>
<h2>精选文章</h2>
<ul>
<li>我们更喜欢的五只股票比 Beam Therapeutics 更好</li>
<li>如何使用股票筛选器寻找股票</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>如何开始投资于便士股票</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年爆炸</li>
<li>最具波动性的股票，投资者需要知道的事项</li>
<li>安海斯 - 布希收购 BeatBox 以赢得年轻饮酒者</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkVBTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkVBTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Beam Therapeutics 吗？</h2>
<p>在你考虑 Beam Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议他们在更广泛的市场注意到之前立即购买……而 Beam Therapeutics 并不在名单上。</p>
<p>虽然 Beam Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BEAM

<p>Beam Therapeutics Inc.（纳斯达克代码：BEAM）获得了十六家研究公司的共识 “适度买入” 评级。分析师设定的平均 12 个月目标价为 45.58 美元。该股票的评级各异，包括卖出、持有、买入和强烈买入。最近的分析师报告包括 HC Wainwright 的 80 美元目标和 Jefferies 的 41 美元目标。Beam 的股票开盘价为 26.48 美元，市值为 26.9 亿美元。机构投资者显著增加了对 Beam Therapeutics 的持股</p>

<p>Beam Therapeutics Inc. (NASDAQ:BEAM - Get Free Report) has earned an average rating of &#34;Moderate Buy&#34; from the sixteen research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $45.5833.</p>
<div class="lb-trans"><p>Beam Therapeutics Inc.（纳斯达克代码：BEAM - 获取免费报告）在目前覆盖该公司的十六家研究机构中获得了 “适度买入” 的平均评级，MarketBeat 报道称。一位研究分析师给予该股票卖出评级，两位给予持有评级，十一位给予买入评级，两位给予强烈买入评级。在过去一年中更新了对该股票覆盖的分析师中，平均十二个月目标价为 45.5833 美元。</p>
</div><p>Get <strong>Beam Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Beam Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>MarketBeat Week in Review – 3/4 – 3/8</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 3/4 – 3/8</li>
</ul>
</div><p>A number of equities research analysts have recently commented on BEAM shares. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $80.00 price target on shares of Beam Therapeutics in a research report on Friday, October 10th. Jefferies Financial Group initiated coverage on shares of Beam Therapeutics in a research note on Thursday, October 9th. They issued a &#34;buy&#34; rating and a $41.00 price target on the stock. Benchmark reiterated a &#34;speculative buy&#34; rating on shares of Beam Therapeutics in a report on Monday, November 17th. Wall Street Zen lowered shares of Beam Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Beam Therapeutics in a research report on Wednesday, October 8th.</p>
<div class="lb-trans"><p>一些股票研究分析师最近对 BEAM 股票发表了评论。HC Wainwright 在 10 月 10 日星期五的研究报告中重申了 “买入” 评级，并设定了 80.00 美元的价格目标。Jefferies Financial Group 在 10 月 9 日星期四的研究报告中开始覆盖 Beam Therapeutics 股票。他们给予该股票 “买入” 评级，并设定了 41.00 美元的价格目标。Benchmark 在 11 月 17 日星期一的报告中重申了对 Beam Therapeutics 股票的 “投机性买入” 评级。华尔街 Zen 在 11 月 8 日星期六的报告中将 Beam Therapeutics 股票的评级从 “持有” 下调至 “卖出”。最后，Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Beam Therapeutics 股票的 “卖出（d-）” 评级。</p>
</div><p><strong>Read Our Latest Research Report on BEAM</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 BEAM 的最新研究报告</strong></p>
</div><h2>Beam Therapeutics Stock Down 2.3%</h2>
<div class="lb-trans"><h2>Beam Therapeutics 股票下跌 2.3%</h2>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治疗许可付款而大幅上涨</li>
</ul>
</div><p>Shares of BEAM stock opened at $26.48 on Wednesday. Beam Therapeutics has a 12-month low of $13.52 and a 12-month high of $35.25. The firm has a fifty day moving average of $24.97 and a 200-day moving average of $21.13. The firm has a market capitalization of $2.69 billion, a price-to-earnings ratio of -5.98 and a beta of 2.21.</p>
<div class="lb-trans"><p>BEAM 股票在星期三开盘价为 26.48 美元。Beam Therapeutics 的 12 个月低点为 13.52 美元，12 个月高点为 35.25 美元。该公司的 50 日移动平均线为 24.97 美元，200 日移动平均线为 21.13 美元。该公司的市值为 26.9 亿美元，市盈率为 -5.98，贝塔值为 2.21。</p>
</div><p>Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.12). Beam Therapeutics had a negative return on equity of 42.86% and a negative net margin of 744.41%.The business had revenue of $9.70 million for the quarter, compared to analyst estimates of $12.83 million. During the same period in the previous year, the business posted ($1.17) EPS. The business's quarterly revenue was down 32.2% compared to the same quarter last year. Research analysts expect that Beam Therapeutics will post -4.57 earnings per share for the current year.</p>
<div class="lb-trans"><p>Beam Therapeutics（纳斯达克代码：BEAM - 获取免费报告）最近在 11 月 4 日星期二发布了季度财报。该公司报告本季度每股收益（EPS）为 -1.10 美元，低于市场共识预期的 -0.98 美元，差距为 -0.12 美元。Beam Therapeutics 的股本回报率为 -42.86%，净利润率为 -744.41%。该公司本季度的收入为 970 万美元，而分析师预期为 1283 万美元。在去年同期，该公司每股收益为 -1.17 美元。与去年同期相比，该公司的季度收入下降了 32.2%。研究分析师预计 Beam Therapeutics 今年的每股收益将为 -4.57 美元。</p>
</div><h2>Institutional Trading of Beam Therapeutics</h2>
<div class="lb-trans"><h2>Beam Therapeutics 的机构交易</h2>
</div><ul>
<li>Is CRISPR Therapeutics the NVIDIA of gene editing?</li>
</ul>
<div class="lb-trans"><ul>
<li>CRISPR Therapeutics 是基因编辑领域的 NVIDIA 吗？</li>
</ul>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Larson Financial Group LLC boosted its holdings in Beam Therapeutics by 4,370.5% during the third quarter. Larson Financial Group LLC now owns 1,967 shares of the company's stock worth $48,000 after purchasing an additional 1,923 shares during the last quarter. Van ECK Associates Corp lifted its position in Beam Therapeutics by 48.7% during the 3rd quarter. Van ECK Associates Corp now owns 2,158 shares of the company's stock worth $52,000 after buying an additional 707 shares in the last quarter. Allworth Financial LP boosted its stake in shares of Beam Therapeutics by 7,080.0% during the 2nd quarter. Allworth Financial LP now owns 2,513 shares of the company's stock worth $43,000 after buying an additional 2,478 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in shares of Beam Therapeutics by 1,248.8% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,817 shares of the company's stock valued at $65,000 after acquiring an additional 3,534 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Beam Therapeutics by 43.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,884 shares of the company's stock valued at $66,000 after acquiring an additional 1,175 shares in the last quarter. 99.68% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Larson Financial Group LLC 在第三季度将其在 Beam Therapeutics 的持股增加了 4370.5%。Larson Financial Group LLC 现在拥有 1,967 股该公司的股票，价值 48,000 美元，此前在上个季度购买了额外的 1,923 股。Van ECK Associates Corp 在第三季度将其在 Beam Therapeutics 的持仓增加了 48.7%。Van ECK Associates Corp 现在拥有 2,158 股该公司的股票，价值 52,000 美元，此前在上个季度购买了额外的 707 股。Allworth Financial LP 在第二季度将其在 Beam Therapeutics 的持股增加了 7080.0%。Allworth Financial LP 现在拥有 2,513 股该公司的股票，价值 43,000 美元，此前在上个季度购买了额外的 2,478 股。大和证券集团在第二季度将其在 Beam Therapeutics 的持股增加了 1248.8%。大和证券集团现在拥有 3,817 股该公司的股票，价值 65,000 美元，此前在上个季度购买了额外的 3,534 股。最后，未来资产全球投资有限公司在第二季度将其在 Beam Therapeutics 的持股增加了 43.4%。未来资产全球投资有限公司现在拥有 3,884 股该公司的股票，价值 66,000 美元，此前在上个季度购买了额外的 1,175 股。目前 99.68% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Beam Therapeutics</h2>
<div class="lb-trans"><h2>关于 Beam Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.</p>
<div class="lb-trans"><p>Beam Therapeutics Inc. 是一家生物技术公司，专注于为美国患有严重疾病的患者开发精准基因药物。它开发了 BEAM-101 用于治疗镰状细胞病或 β-地中海贫血；以及 BEAM-302，一种针对严重 α-1 抗胰蛋白酶缺乏症的肝靶向 LNP 配方；BEAM-201，一种抗 CD7 CAR-T 产品候选药物，目前正在进行 1/2 期临床试验，用于治疗难治性 T 细胞急性淋巴细胞白血病/T 细胞淋巴母细胞瘤；以及 BEAM-301，一种用于治疗糖原储存病 1a 的肝靶向 LNP 配方。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Beam Therapeutics</li>
<li>How to Use Stock Screeners to Find Stocks</li>
<li>Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 Retailers</li>
<li>How to start investing in penny stocks</li>
<li>10X Gains? These 3 Robotics Stocks Could Explode by 2035</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>Anheuser-Busch Buys BeatBox to Win Over Younger Drinkers</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Beam Therapeutics 更好</li>
<li>如何使用股票筛选器寻找股票</li>
<li>消费者得到了煤炭，但圣诞老人给这两家零售商带来了巨大的收益</li>
<li>如何开始投资于便士股票</li>
<li>10 倍收益？这三只机器人股票可能在 2035 年爆炸</li>
<li>最具波动性的股票，投资者需要知道的事项</li>
<li>安海斯 - 布希收购 BeatBox 以赢得年轻饮酒者</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkVBTQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=BEAM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Beam Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Beam Therapeutics 吗？</h2>
</div><p>Before you consider Beam Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Beam Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议他们在更广泛的市场注意到之前立即购买……而 Beam Therapeutics 并不在名单上。</p>
</div><p>While Beam Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Beam Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Beam Therapeutics Inc.（NASDAQ:BEAM）被分析师一致推荐为 “适度买入”